<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602872</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-OAR-BW-001</org_study_id>
    <nct_id>NCT03602872</nct_id>
  </id_info>
  <brief_title>Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Osteoarthritis</brief_title>
  <official_title>Phase I, Open Label Study to Assess the Safety and Tolerance of a Single Intraarticular Dose of STEMEDICA's Human Allogeneic Bone Marrow Derived Mesenchymal Stem Cells, in Subjects With Knee Osteoarthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Santa Clarita, Mexico</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Santa Clarita, Mexico</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the safety of Stemedica's mesenchymal stem cells in
      patients with knee osteoarthritis. The route of administration is intraarticular. Safety will
      be evaluated by AE/SAE incidence and administration tolerance. The subjects will undergo
      follow-up for 52 weeks. The target population is subjects with knee osteoarthritis (grade
      II-III in Kellgren-Lawrence scale).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor to start with different protocol, postponed due to COVID
  </why_stopped>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation of all AE/SAEs</measure>
    <time_frame>From the first dosing of the first subject up to 30 days after the last follow up of the last dosed subject</time_frame>
    <description>All AE/SAE will be assessed for causality and reported utilizing MedDRA terminology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure tolerance (procedure pain/discomfort incidence)</measure>
    <time_frame>7 days after subject receives dosing</time_frame>
    <description>The procedure tolerance will be evaluated through a questionnaire for procedure pain/discomfort incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC questionnaire</measure>
    <time_frame>From the first dosing of the first subject up to 30 days after the last follow up of the last dosed subject</time_frame>
    <description>The WOMAC questionnaire will be used to evaluate any preliminary efficacy findings throughout the study completion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OAKHQOL questionnaire</measure>
    <time_frame>From the first dosing of the first subject up to 30 days after the last follow up of the last dosed subject</time_frame>
    <description>The OAKHQOL questionnaire will be used to evaluate any preliminary efficacy findings throughout the study completion.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human allogeneic mesenchymal bone marrow derived stem cells</intervention_name>
    <description>Intraarticular administration of 20x10^6 MSCs</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female volunteers between 35-65 years.

          -  X-ray evidence of osteoarthritis (grade II-III in Kellgren-Lawrence).

          -  Chronic joint pain (&gt;5 visual analogue scale) in knee.

          -  BMI ≤ 29.

          -  Voluntary acceptance and signature of informed consent.

          -  Willing to attend study visits and lab sample recollection.

          -  Lab values within normal reference values.

          -  Willing to use effective birth control methods.

        Exclusion Criteria:

          -  Inflammatory arthritis.

          -  Generalized infection.

          -  Active cancer or history of cancer in the past 5 years.

          -  Receiving oral or intraarticular steroids.

          -  Positive labs for HIV, Hepatitis B or C.

          -  Recent trauma in the target joint.

          -  Debris in joint.

          -  Subjects that have undergone or need to undergo arthroscopic knee surgery in the
             target joint.

          -  History of joint substitution, intraarticular fractures, osteotomy, arthroplasty or
             menisectomy.

          -  Clinically significant knee misalignment.

          -  Other illnesses that the investigator considers clinically significant.

          -  Participating in another clinical trial three months before enrolling.

          -  Women that are pregnant, lactating or result positive in the pregnancy test during
             screening.

          -  Known allergies to bovine products.

          -  Subjects taking anticoagulants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José F Izquierdo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>External</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Santa Clarita</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California</state>
        <zip>22000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee osteoarthritis, safety, MSCs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

